I do have a position given that their antibiotic trial will likely be successful, as will their clotting trial. But based on their historical pattern, a successful trial might well be followed closely by another offering. So that tempers my enthusiasm some.
Really their antibiotic program belongs in the hands of a big pharma that can develop it properly. Based on what we have seen so far it has tremendous potential and should be developed on a much broader basis than they are capable of doing themselves. Not sure why they haven't been able to partner at least some programs, like the ones for oral cavity infections.
Market Data 
Markets 
AI
